SII developing first vaccine for rare Bundibugyo strain, which currently lacks approved protection despite ongoing outbreak in DRC and Uganda. Vaccine uses proven Oxford-AstraZeneca Covid platform technology, enabling faster manufacturing and scale-up for clinical testing and deployment.
India's Serum Institute Fast-Tracks Ebola Vaccine for Rare Bundibugyo Strain
Over 1,500 suspected Ebola cases and more than 650 deaths recorded in Democratic Republic of Congo and Uganda since outbreak began in 2026.
No approved vaccine existed for a virus that was actively spreading.
Mark
Why does Bundibugyo matter more now than it did before this outbreak?
Mimi
Because it's spreading, and there was no vaccine ready. Zaire got attention because it killed thousands in West Africa. Bundibugyo stayed in the background, rare enough that no one invested in protection. Now it's active, and the world has to catch up.
Mark
How much faster can they move with the Oxford platform?
Mimi
The platform is already proven. They know how to manufacture it, how to scale it. Instead of building the factory while designing the vaccine, they can start production almost immediately once the clinical candidate is ready. That's months, not years.
Mark
Is India at risk?
Mimi
Not currently. But airports are screening because the virus doesn't respect borders. One traveler, one case—that changes everything. The screening is insurance.
Mark
What happens if the vaccine works?
Mimi
It gets deployed to the outbreak zones first. But more than that, it becomes part of the arsenal for the next time Bundibugyo emerges. That's what Tedros meant about preparedness. You stop fighting the last war and start preparing for the next one.
Mark
Who actually benefits from this partnership?
Mimi
Everyone. Oxford brings the platform and credibility. CEPI brings funding and coordination. The Serum Institute brings manufacturing capacity at scale. Africa CDC knows the ground. WHO moves the bureaucracy. Without all of them, this doesn't happen as fast.
The Pulse
- Over 1,500 suspected Ebola cases and more than 650 deaths in DRC and Uganda since outbreak began in 2026
- ChAdOx1 BDBV vaccine uses Oxford-AstraZeneca Covid platform technology for faster manufacturing
- Serum Institute partnering with University of Oxford, CEPI, WHO, and Africa CDC on vaccine development
SII developing first vaccine for rare Bundibugyo strain, which currently lacks approved protection despite ongoing outbreak in DRC and Uganda. Vaccine uses proven Oxford-AstraZeneca Covid platform technology, enabling faster manufacturing and scale-up for clinical testing and deployment.
Serum Institute of India is fast-tracking development of ChAdOx1 BDBV vaccine against Bundibugyo Ebola strain in collaboration with Oxford and WHO, as outbreak spreads in Central Africa.
India's Serum Institute is moving fast to fill a critical gap in global disease defense. For the first time, a vaccine is being developed specifically for the Bundibugyo strain of Ebola—a variant that has no approved protection despite spreading through the Democratic Republic of Congo and Uganda in an outbreak that began earlier this year. The institute is not working alone. It has partnered with the University of Oxford and the Coalition for Epidemic Preparedness Innovations, with backing from the World Health Organization and Africa's disease control agency. The vaccine candidate, called ChAdOx1 BDBV, represents a direct response to an outbreak that has already claimed more than 650 lives among over 1,500 suspected cases.
Bundibugyo is not the Ebola strain most people have heard of. The Zaire variant, which caused the devastating West African epidemic of 2014-2016, has vaccines. Bundibugyo does not. This absence matters enormously when the virus is actively spreading. The Serum Institute's decision to prioritize this particular strain reflects both the urgency of the current situation and the recognition that future outbreaks could strike anywhere. The vaccine uses the same technological platform that produced the Oxford-AstraZeneca Covid-19 vaccine—a proven system that allows manufacturers to move from design to large-scale production relatively quickly once clinical-grade doses are ready for testing.
The World Health Organization has already accelerated its assessment process for the vaccine candidate, a sign of how seriously global health authorities are treating the outbreak. Tedros Adhanom Ghebreyesus, the WHO's director-general, has stated that a working vaccine against Bundibugyo could help contain the current epidemic and prepare the world for future threats. Jean Kaseya, who leads Africa's disease control agency, has confirmed that the Serum Institute will manufacture the vaccine—a significant commitment from one of the world's largest vaccine producers by volume.
India itself has reported no active cases of Ebola, but the country is not taking chances. Health authorities and airports have tightened screening procedures for travelers arriving from affected regions, with isolation protocols in place for anyone showing symptoms. The measures reflect a lesson learned from previous outbreaks: containment begins at borders and in surveillance systems, not after the virus arrives.
What makes this moment distinct is the speed of response and the clarity of purpose. Governments and vaccine makers are no longer waiting for an outbreak to reach a certain scale before mobilizing resources. The Bundibugyo outbreak has triggered an immediate, coordinated effort to develop protection against a strain that, until now, had been largely neglected by the global vaccine industry. The race is on to move from laboratory to clinic to deployment—and the Serum Institute is now central to that effort.
Notable Quotes
A vaccine against the Bundibugyo strain could help control the current epidemic and strengthen preparedness for future outbreaks.— WHO Director-General Tedros Adhanom Ghebreyesus
The vaccine will be manufactured by the Serum Institute of India.— Africa CDC Director-General Jean Kaseya
Want the full story?
Read the original at NDTV.com ↗
Health & Medicine